Trajectories of Depressive Individual Symptoms over Time during Transcranial Photobiomodulation DOI Creative Commons

M. Urata,

Paolo Cassano, Richard J. Norton

et al.

Photonics, Journal Year: 2023, Volume and Issue: 10(12), P. 1324 - 1324

Published: Nov. 29, 2023

Transcranial photobiomodulation (t-PBM) is an innovative, non-invasive treatment for depression. This study aimed to investigate the changes in individual depressive symptoms during t-PBM and identify that improved those who responded treatment. The research analyzed data from two trials, Evaluation of Light-emitting diodes Therapeutic Effect Depression-2 -3, focusing on patients with major disorder. received F3 F4 regions scalp over eight weeks, assessed weekly using Quick Inventory Depression Symptomatology (QIDS). A response was defined as a 50% or greater reduction QIDS score at weeks baseline. Out 21 analyzed, 4 weeks. Neurovegetative symptoms, including sleep disturbances change appetite, ≥50% had these However, core depressed mood lack energy, persisted about 80–90% patients. responders showed more than 75% improvement symptoms. These findings suggest may uniquely alleviate certain neurovegetative depression, might be linked clinical this

Language: Английский

Photobiomodulation in the aging brain: a systematic review from animal models to humans DOI Creative Commons

Lucia Rodríguez-Fernández,

Candela Zorzo,

Jorge L. Arias

et al.

GeroScience, Journal Year: 2024, Volume and Issue: unknown

Published: June 11, 2024

Abstract Aging is a multifactorial biological process that may be associated with cognitive decline. Photobiomodulation (PBM) non-pharmacological therapy shows promising results in the treatment or prevention of age-related impairments. The aim this review to compile preclinical and clinical evidence effect PBM during aging healthy pathological conditions, including behavioral analysis neuropsychological assessment, as well brain-related modifications. 37 studies were identified by searching PubMed, Scopus, PsycInfo databases. Most use wavelengths 800, 810, 1064 nm but intensity days application highly variable. In animal studies, it has been shown improvements spatial memory, episodic-like social while different have found recognition memory. Locomotor activity improved Parkinson disease models. aged humans, outlined working inhibition, lexical/semantic access, general cognition was mainly enhanced on Alzheimer mild impairment. Anxiety assessment scarce mixed results. As for brain activity, outline effects reversing metabolic alterations enhancing mitochondrial function, evidenced restored CCO ATP levels. Additionally, demonstrated neuroprotective, anti-inflammatory, immunomodulatory hemodynamic effects. findings suggest holds promise non-invasive intervention modulation functional reorganization. It necessary develop standardized protocols correct, beneficial, homogeneous PBM.

Language: Английский

Citations

7
Neuroprotection in pentylenetetrazol kindling rat model: A synergistic approach with eugenol and photobiomodulation DOI
Haitham S. Mohammed, Dalia Ahmed, Yasser A. Khadrawy

et al.

Brain Research, Journal Year: 2025, Volume and Issue: unknown, P. 149645 - 149645

Published: April 1, 2025

Language: Английский

Citations

0
Photobiomodulation (PBMT) and Its Interface with Sleep Dentistry: Clinical Case Report DOI Creative Commons
Vitor Hugo Panhóca, Carolina Álvarez, Viviane Brocca de Souza

et al.

Published: May 13, 2024

INTRODUCTION: This study aimed to evaluate and raise the therapeutic hypothesis of use Photobiomodulation (PBMT) as a complementary therapy in patients with sleep disorder (SD) broad approach involving other pathologies superimposed on this pathology. METHODS: is clinical case report patient Parkinson's disease (PD) complaining disorder. The proposed treatment photobiomodulation intraoral application using an innovative dosimetry. SD was assessed adapted analogue scale. RESULTS: In evaluation performed after last session, there improvement compared pre-treatment evaluation. However, one month end treatment, it observed that quality remained practically same. CONCLUSION: results present suggest could become new perspective for disorders (SD). controlled, randomized studies must be carried out strengthen confirm evidence report.

Language: Английский

Citations

0
Trajectories of Depressive Individual Symptoms over Time during Transcranial Photobiomodulation DOI Creative Commons

M. Urata,

Paolo Cassano, Richard J. Norton

et al.

Photonics, Journal Year: 2023, Volume and Issue: 10(12), P. 1324 - 1324

Published: Nov. 29, 2023

Transcranial photobiomodulation (t-PBM) is an innovative, non-invasive treatment for depression. This study aimed to investigate the changes in individual depressive symptoms during t-PBM and identify that improved those who responded treatment. The research analyzed data from two trials, Evaluation of Light-emitting diodes Therapeutic Effect Depression-2 -3, focusing on patients with major disorder. received F3 F4 regions scalp over eight weeks, assessed weekly using Quick Inventory Depression Symptomatology (QIDS). A response was defined as a 50% or greater reduction QIDS score at weeks baseline. Out 21 analyzed, 4 weeks. Neurovegetative symptoms, including sleep disturbances change appetite, ≥50% had these However, core depressed mood lack energy, persisted about 80–90% patients. responders showed more than 75% improvement symptoms. These findings suggest may uniquely alleviate certain neurovegetative depression, might be linked clinical this

Language: Английский

Citations

0